INSYS Therapeutics, Inc.
http://www.insysrx.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From INSYS Therapeutics, Inc.
Minute Insight: Current Testing Technologies Can Detect The Omicron Variant
As fears about vaccine escape grow, test manufacturers have been quick to assert that their tests can spot the new Omicron variant of SARS-CoV-2
Finance Watch: CF Foundation Commits $110m In Partnership With Flagship’s Pioneering Medicines
Private Company Edition: Flagship’s Pioneering Medicines initiative and the firm’s portfolio companies will deliver cystic fibrosis drug candidates. Also, recent venture capital financings include cloud technology firm Saama’s $430m round and Shoreline’s $140m in new funding.
Agenus PD-1 Down But Not Out With Cervical Cancer BLA Withdrawal
The company announced it would withdraw the BLA for balstilimab monotherapy in cervical cancer following Keytruda’s full approval, but it plans to keep developing the drug.
COVID-19: FDA Tells Test Makers How To Minimize Effects Of Variants
The US Food and Drug Administration has taken additional steps to ensure mutations of the COVID-19 virus do not negatively impact the efficacy of tests.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Other Names / Subsidiaries
-
- NeoPharm, Inc.
- Fresenius Biotech GmbH
- Neovii Biotech GmbH